Combination therapy in treatment of experimental pulmonary aspergillosis: in vitro and in vivo correlations of the concentration- and dose- dependent interactions between anidulafungin and voriconazole by Bliss independence drug interaction analysis - Wikidata - wikimedia - TriplyDB

Combination therapy in treatment of experimental pulmonary aspergillosis: in vitro and in vivo correlations of the concentration- and dose- dependent interactions between anidulafungin and voriconazole by Bliss independence drug interaction analysis

Combination therapy in treatment of experimental pulmonary aspergillosis: in vitro and in vivo correlations of the concentration- and dose- dependent interactions between anidulafungin and voriconazole by Bliss independence drug interaction analysis

http://www.wikidata.org/entity/Q37204192

about

Inhibition of ion channels and heart beat in Drosophila by selective COX-2 inhibitor SC-791 Combination of voriconazole and anidulafungin for treatment of triazole-resistant aspergillus fumigatus in an in vitro model of invasive pulmonary aspergillosis Anidulafungin and voriconazole in invasive fungal disease: pharmacological data and their use in combination.Defining fractional inhibitory concentration index cutoffs for additive interactions based on self-drug additive combinations, Monte Carlo simulation analysis, and in vitro-in vivo correlation data for antifungal drug combinations against Aspergillu A formal model for analyzing drug combination effects and its application in TNF-alpha-induced NFkappaB pathway Rodent Models of Invasive Aspergillosis due to Aspergillus fumigatus: Still a Long Path toward Standardization.Population pharmacokinetic analysis of voriconazole and anidulafungin in adult patients with invasive aspergillosis.Practice Guidelines for the Diagnosis and Management of Aspergillosis: 2016 Update by the Infectious Diseases Society of America.In vitro combination of isavuconazole with micafungin or amphotericin B deoxycholate against medically important molds.Efficacy of combination therapy of triazole and echinocandin in treatment of invasive aspergillosis: a systematic review of animal and human studies Synergistic interaction of the triple combination of amphotericin B, ciprofloxacin, and polymorphonuclear neutrophils against Aspergillus fumigatus Antifungal pharmacokinetics and pharmacodynamics In vitro combination of anidulafungin and voriconazole against intrinsically azole-susceptible and -resistant Aspergillus spp In vitro interaction of voriconazole and anidulafungin against triazole-resistant Aspergillus fumigatus.Pharmacokinetics and Concentration-Dependent Efficacy of Isavuconazole for Treatment of Experimental Invasive Pulmonary Aspergillosis.Environmental monitoring for Aspergillus fumigatus in association with an immunosuppressed rabbit model of pulmonary aspergillosis.Impact of in vivo triazole and echinocandin combination therapy for invasive pulmonary aspergillosis: enhanced efficacy against Cyp51 mutant isolates Bronchopulmonary disposition of intravenous voriconazole and anidulafungin given in combination to healthy adults.Efficacy of the combination of voriconazole and caspofungin in experimental pulmonary aspergillosis by different Aspergillus species.Echinocandin pharmacodynamics: review and clinical implications.Use of Antifungal Combination Therapy: Agents, Order, and Timing.Pharmacokinetics, antifungal activity and clinical efficacy of anidulafungin in the treatment of fungal infections.Anidulafungin: is it a promising option in the treatment of pediatric invasive fungal infections?Anidulafungin: when and how? The clinician's view.Combination antifungal therapy for invasive fungal infections in children and adults.Antifungal combination therapy for invasive aspergillosis.Consensus guidelines for the treatment of invasive mould infections in haematological malignancy and haemopoietic stem cell transplantation, 2014.Echinocandins: The Expanding Antifungal Armamentarium.Combination therapy for the treatment of pulmonary mold infections.Animal Models for Studying Triazole Resistance in Aspergillus fumigatus.Combination Therapy with Isavuconazole and Micafungin for Treatment of Experimental Invasive Pulmonary Aspergillosis.Endpoint Assessment in Rabbit Models of Invasive Pulmonary Aspergillosis and Mucormycosis.New pharmacological opportunities for the treatment of invasive mould diseases.Dose optimization of voriconazole/anidulafungin combination against Aspergillus fumigatus using an in vitro pharmacokinetic/pharmacodynamic model and response surface analysis: clinical implications for azole-resistant aspergillosis.Assessment of efficacy of antifungals against Aspergillus fumigatus: value of real-time bioluminescence imaging.The Natural Antimicrobial Subtilosin A Synergizes with Lauramide Arginine Ethyl Ester (LAE), ε-Poly-L-lysine (Polylysine), Clindamycin Phosphate and Metronidazole, Against the Vaginal Pathogen Gardnerella vaginalis.Susceptibility breakpoints and target values for therapeutic drug monitoring of voriconazole and Aspergillus fumigatus in an in vitro pharmacokinetic/pharmacodynamic model.Clinical experience of anidulafungin for the treatment of patients with documented candidemia.Multicentre surveillance study on feasibility, safety and efficacy of antifungal combination therapy for proven or probable invasive fungal diseases in haematological patients: the SEIFEM real-life combo study.Combined therapy of voriconazole and anidulafungin in murine infections by Aspergillus flavus.

P2860

Q28484132-706B4D76-C289-420E-805F-E3C87DD59106 Q28727508-6B4BEECB-FB8A-4B50-9468-7C67E868BF68 Q33490772-9302E827-1F8B-4499-A9B3-9961362A765B Q33517581-7602303A-15C0-403E-8A52-7E9828CAB928 Q33563358-46A1A000-04F5-4822-BFC5-1CFEF7F750DA Q33689767-3F707153-6750-4B1E-8BE3-08EBB307B277 Q34058346-966DEC95-5DF5-4490-9A6E-2996A7446282 Q34532546-6F0EE80F-79FB-40D8-961A-30F3DCE75C24 Q34596443-EFE6029F-88B2-482F-A6F2-CAF3FB6710C8 Q35113648-4D7AED00-A86F-4DB6-9775-A0E5ABB2DE23 Q35598556-0A8169B8-7EF0-4EE6-9145-55B0ED3E61A0 Q35663841-087A0070-DCB6-4E39-954F-B8C78E18E302 Q36171554-0899EC4F-44FB-4EB8-BE24-7872B2A59A7D Q36558484-5AB2B795-9CC6-4691-8215-989278CC0549 Q36887855-7D9573EB-8CC0-42EB-8B7C-EB6C6F1B5CC9 Q37201086-750DF988-4766-43D7-8E61-CDE71574C995 Q37263430-9B180FC4-14A5-448F-BBE8-2E1F9283A9DB Q37450705-01FEC563-5251-4624-AC75-92FDBF379EA6 Q37558822-92164544-1C6B-46F4-9E0D-D699F220B8E3 Q37718385-3C2EE89C-B72B-46FC-B398-6F0B5204CBD9 Q37767359-1C3B4037-9D93-4450-AAC1-F2B6ED9F9487 Q37785979-BC941F1D-2EB7-4EAA-950F-E136A3700941 Q37854724-BE1FF010-3213-4C13-BFFB-B01CB6EF5BB2 Q37888751-1C794C7B-6622-4541-94B4-C8417006C834 Q38102782-76A18C8E-BED5-41AD-9F98-D5E27D2F7424 Q38232492-ABCCDBCA-1CBA-40F5-B4BC-9B6C1B841F15 Q38284463-74976C42-49F9-4AE8-A381-1525553B9410 Q38633102-0A235C60-A10D-4689-97D9-AE70CF4BA4E8 Q38806932-05A2F2F2-B851-4EAC-B5B2-F8152141192D Q40045642-6022E171-BB71-4907-8321-05225D8D7730 Q40140001-561A39FD-AE52-42AC-AE84-51AC4AE1D97A Q40183751-48026A3B-610E-4226-B01E-0F2EA44D4E53 Q40273481-B8519D03-A8BE-417E-8BB1-01CBC640916B Q40587101-D4708F63-01A4-4350-8B9F-B705B005329B Q41441699-AB607FA6-63B7-439A-A4C7-B81AC5207B87 Q41544969-E5411C46-61EB-4992-BBB7-D2F3E6FA541D Q42227869-4D7BD515-B3C0-4F8B-AF50-CE2B4CB6C973 Q42751895-C069F757-752A-4FDC-938F-01151C5018EC Q43718029-40D3C225-DF01-44CF-9D1B-BC0B59ECC9B9 Q44619968-CC0B25B1-E1F2-43B5-BBBE-BE2C498224C0

P2860

Combination therapy in treatment of experimental pulmonary aspergillosis: in vitro and in vivo correlations of the concentration- and dose- dependent interactions between anidulafungin and voriconazole by Bliss independence drug interaction analysis

http://www.wikidata.org/entity/Q37204192

description

article científic

@ca

article scientifique

@fr

articolo scientifico

@it

artigo científico

@pt

bilimsel makale

@tr

scientific article published on 23 March 2009

@en

vedecký článok

@sk

vetenskaplig artikel

@sv

videnskabelig artikel

@da

vědecký článek

@cs

name

Combination therapy in treatme ...... ence drug interaction analysis

@en

Combination therapy in treatme ...... ence drug interaction analysis

@nl

type

label

Combination therapy in treatme ...... ence drug interaction analysis

@en

Combination therapy in treatme ...... ence drug interaction analysis

@nl

prefLabel

Combination therapy in treatme ...... ence drug interaction analysis

@en

Combination therapy in treatme ...... ence drug interaction analysis

@nl

P1433

Q37204192-3B0EF588-4BB8-49C2-9350-CBA2BB525F03

P1476

Q37204192-755D2370-D688-4A52-BE1E-6F063E050CD9

P2093

Q37204192-0227F454-7D34-4539-B392-1FA8A38E144A

Q37204192-375DCE9F-CFE6-4AC7-9E15-8B96E3FFFA64

Q37204192-5F82963C-3F58-4940-8C61-B31600817B4E

Q37204192-668AF21B-7F75-4E5D-BC1A-B22E7330662C

Q37204192-7082C7BB-A48F-49B2-9805-CA03D98131FF

Q37204192-B84AECE4-7348-4B1D-B508-16D2BEA925B7

Q37204192-CA516FB9-E72B-488A-8025-209A7458FB1A

Q37204192-D43059EE-378F-4BCA-BDA6-A65BAF99E224

Q37204192-D8174784-5502-43F7-9CDD-A09F07E44B79

Q37204192-E1EACDC8-DDF8-47A5-A66C-A0F1819C72E3

P2860

Q37204192-03AA0C6C-664C-4F3A-8DAF-6AE246187E17

Q37204192-09114851-F431-4592-AEEE-63E360CB43AF

Q37204192-0A7F6C1E-2E3F-4B00-8890-57B9404B27B4

Q37204192-0FCA82BB-502B-47DF-AF27-F315A16AC752

Q37204192-104B907C-F2F2-48F0-8D04-440478D45AFE

Q37204192-1FCC36D0-8F96-45FA-B7A6-FEC936CE1ACC

Q37204192-21C88C78-0266-457D-B5D0-67B1626E2A9C

Q37204192-3590BA9E-02E2-49A3-988F-3C4D4864FF78

Q37204192-3B9F5F72-BC06-4399-A0AE-AF63F253C43A

Q37204192-40BE718A-3CC5-4BF3-9D82-8207F293B994

P304

Q37204192-9AE8CAD4-E65F-430A-BF8B-79062AAD6AA4

P31

Q37204192-237FD9CF-A5D0-4873-A0B2-FEA21C8306F4

P356

Q37204192-E2D08E56-84AD-4D7B-922C-ADC49580FBD5

P407

Q37204192-BB9677ED-E705-4646-A5A0-8DC9112AF7AE

P433

Q37204192-0D1D5FFD-1A22-4859-9718-E2BD2AB7F903

P478

Q37204192-B1FEC05E-1C31-4822-A171-D06E03193A60

P50

Q37204192-5140B822-7AA1-4B34-9E7F-0B9E362089E0

Q37204192-C66A3C51-784C-41D1-9205-B0E4832CAC9A

P577

Q37204192-2B4E7DE4-21B5-47AF-BD7F-A8338327B92E

P698

Q37204192-0BE2D343-9978-48C8-A804-3958437BAE66

P921

Q37204192-FCA526D5-45A3-48E4-B6C9-FFB4DD6B0707

P932

Q37204192-E1E24D9B-D4F3-46B3-A22D-054C05FFD2DD

P356

P1433

Antimicrobial Agents and Chemotherapy

P1476

Combination therapy in treatme ...... ence drug interaction analysis

@en

P2093

Andrea Francesconi

http://www.w3.org/2001/XMLSchema#string

Diana Mickiene

http://www.w3.org/2001/XMLSchema#string

Johanna E Hughes

http://www.w3.org/2001/XMLSchema#string

John Bacher

http://www.w3.org/2001/XMLSchema#string

Joseph Meletiadis

http://www.w3.org/2001/XMLSchema#string

Margaret P Cotton

http://www.w3.org/2001/XMLSchema#string

Miki Kasai

http://www.w3.org/2001/XMLSchema#string

Nilo A Avila

http://www.w3.org/2001/XMLSchema#string

Robert L Schaufele

http://www.w3.org/2001/XMLSchema#string

Ruta Petraitiene

http://www.w3.org/2001/XMLSchema#string

P2860

Antifungal activities of posaconazole, ravuconazole, and voriconazole compared to those of itraconazole and amphotericin B against 239 clinical isolates of Aspergillus spp. and other filamentous fungi: report from SENTRY Antimicrobial Surveillance P

Rat monoclonal antibodies against Aspergillus galactomannan

Antifungal activity and pharmacokinetics of posaconazole (SCH 56592) in treatment and prevention of experimental invasive pulmonary aspergillosis: correlation with galactomannan antigenemia

Aspergillus fumigatus and aspergillosis

Update on antifungals targeted to the cell wall: focus on beta-1,3-glucan synthase inhibitors.

Morphological effects of lipopeptides against Aspergillus fumigatus correlate with activities against (1,3)-beta-D-glucan synthase.

Pharmacokinetic and pharmacodynamic modeling of anidulafungin (LY303366): reappraisal of its efficacy in neutropenic animal models of opportunistic mycoses using optimal plasma sampling

Invasive aspergillosis. Disease spectrum, treatment practices, and outcomes. I3 Aspergillus Study Group.

Chronic forms of pulmonary aspergillosis.

Multidimensional volumetric imaging of pulmonary infiltrates for measuring therapeutic response to antifungal therapy in experimental invasive pulmonary aspergillosis.

P304

2382-2391

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1128/AAC.00329-09

http://www.w3.org/2001/XMLSchema#string

P407

P433

6

http://www.w3.org/2001/XMLSchema#string

P478

53

http://www.w3.org/2001/XMLSchema#string

P50

Theodouli Stergiopoulou

P577

2009-03-23T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P698

19307368

http://www.w3.org/2001/XMLSchema#string

P921

P932

2687223

http://www.w3.org/2001/XMLSchema#string